美国食品药品监督管理局（FDA）已正式向雅培（Abbott Laboratories）旗下糖尿病护理部门授予上市许可，批准其Libre Duo 10天产品进入市场。这一许可经由De Novo预市审查途径获得，标志着该产品在监管审批上迈出关键一步。
美国食品药品监督管理局（FDA）已正式向雅培（Abbott Laboratories）旗下糖尿病护理部门授予上市许可，批准其Libre Duo 10天产品进入市场。这一许可经由De Novo预市审查途径获得，标志着该产品在监管审批上迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.